AzTrials
AzTrials

Genitourinary Syndrome of Menopause (GSM)Early Phase 1NCT07160127

A Clinical Study of Chinese Herbal Formula TJAOA103 in Treating Genitourinary Syndrome of Menopause

A Early Phase 1 study testing TJAOA103 in people with Genitourinary Syndrome of Menopause (GSM), run by Tongji Hospital at 1 site in China.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

The goal of this clinical trial is to learn if Chinese herbal formula TJAOA103 works to treat genitourinary syndrome of menopause (GSM). It will also learn about the safety of TJAOA103. The main questions it aims to answer are: 1. Read more about this study

Who is it for?
Ages 45 to 70 years, women only
What is being tested?
TJAOA103
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
113 participants
Where
1 siteChina
Study dates
15 Sep 2025to 15 Sep 2027
Phase
Early Phase 1
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 45 to 70 years
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Females aged 45-70 years during the menopausal transition or postmenopausal period.
  • Presence of at least one moderate-to-severe (score ≥ 2) symptom of GSM, including vulvovaginal dryness, or vulvovaginal itching/irritation, or vulvovaginal burning/pain, or dyspareunia, or dysuria/urinary frequency/urgency.
  • Willing to participate in this trial and sign a written informed consent form.

Who cannot join

  • Acute or recurrent genitourinary infection.
  • Acute or chronic dermatosis of the vulva or vagina.
  • A grade 3 or higher degree of prolapse according to the Pelvic Organ Prolapse Quantification (POP-Q) system.
  • Unexplained abnormal uterine bleeding.
  • Ovarian/adnexal mass ≥ 4 cm, or adenomyosis, or adenomyoma/uterine myoma ≥ 4 cm.
  • Breast Imaging Reporting and Data System (BI-RADS) classification of breast ultrasound ≥ 4.
Show all 15Show fewer
  • Presence of precancerous lesions or diagnosed malignancy.
  • Liver or kidney function indicators (ALT, AST, Urea, Cr) exceeding the upper limits of reference ranges upon repeated testing.
  • Severe primary diseases of the nervous, circulatory, respiratory, digestive, urinary or hematopoietic systems; or mental diseases;
  • Known allergy to any specific ingredient of the trial drugs.
  • Systemic hormone therapy within the past 2 months.
  • Application of vaginal moisturizers, lubricants, hormone preparations, or alternative therapies for GSM within the past month.
  • Current participation in another clinical trial or participation in another trial within the past month.
  • Unwillingness to discontinue the use of moisturizers, lubricants, or any form of hormonal drugs during the trial.
  • Other conditions deemed unsuitable for participation by the investigators.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Jinjin Zhang, Associate Professor contact

+8613469995233

jinjinzhang@tjh.tjmu.edu.cn

China1 site
  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan

    Jinjin Zhang, Associate Professor, +8613469995233, jinjinzhang@tjh.tjmu.edu.cn

    Yueyue Gao, 2024tj0062@hust.edu.cn

Other trials in China

About this study

Official title: The Efficacy and Safety of Chinese Herbal Formula TJAOA103 for the Treatment of Genitourinary Syndrome of Menopause: A Prospective and Single-Arm Study

The goal of this clinical trial is to learn if Chinese herbal formula TJAOA103 works to treat genitourinary syndrome of menopause (GSM). It will also learn about the safety of TJAOA103. The main questions it aims to answer are:

  1. Does TJAOA103 alleviate the symptoms of GSM in participants or have any other benefits?
  2. What medical problems do participants have when taking TJAOA103? Researchers will conduct a pre-post comparison to see if TJAOA103 works to treat GSM.

Participants will:

  1. Take TJAOA103 twice daily for 4 to 12 weeks.
  2. Complete the tests and/or questionnaires on schedule through online follow-up or outpatient visits.
  3. Record their use of TJAOA103 and any adverse events.
Read the detailed description

Genitourinary syndrome of menopause (GSM) refers to a collection of symptoms and signs such as atrophy of the genital and urinary tracts and sexual dysfunction in women during the menopausal transition and postmenopausal period due to the decline in estrogen and other sex hormone levels. The primary pathogenesis is rooted in ovarian aging. GSM not only causes persistent discomfort and increases the risk of infections but also significantly impairs sexual function and self-esteem in middle-aged and older women. Furthermore, the failure of ovarian hormone function will markedly elevate the risk of aging-related diseases such as cardiovascular events, Alzheimer's disease, and osteoporosis in these patients, shortening their healthspan and increasing all-cause mortality. Therefore, timely intervention for GSM is crucial.

At present, vaginal moisturizers, lubricants, and vaginal estrogen preparations are commonly used in clinical practice to alleviate the symptoms of GSM. Vaginal moisturizers and lubricants help protect the vaginal epithelium and maintain an acidic vaginal environment, but may cause vaginal burning, infections, or allergic reactions. Vaginal estrogen preparations exert their effects on estrogen receptors within the genitourinary system, yet the long-term safety remains uncertain. Ospemifene, a selective estrogen receptor modulator, is another treatment option; however, its weak estrogenic effects may pose risks of thrombosis or endometrial thickening with prolonged use. In addition, laser therapy has also been employed for GSM, but carries potential safety risks including vaginal burns, scarring, and chronic pain.

Traditional Chinese medicine (TCM) possesses distinctive advantages in anti-aging strategies, addressing both symptoms and root causes with commendable safety profiles, thereby rendering it particularly appropriate for middle-aged and elderly populations. Numerous studies have demonstrated the effectiveness of TCM in the management of GSM-related conditions, such as postmenopausal vaginal dryness, atrophic vaginitis, and menopausal urethral syndrome. However, due to the limited understanding of the disease, existing TCM prescriptions have lacked specificity for GSM and often rely on empirical combinations without solid scientific foundation. To solve this problem, we have invented a novel TCM formula, Tongji Anti-Ovarian Aging 103 (TJAOA103). First, we performed an extensive literature retrieval to collect TCM prescriptions effective in alleviating GSM-associated symptoms. Using the TCM Inheritance Support System and the TCM Systems Pharmacology Database and Analysis Platform, we screened out a variety of candidate Chinese herbs and combinations with potential therapeutic effects on GSM, based on its pathogenesis. Then, a panel of senior experts in gynecology, TCM, and pharmacy thoroughly discussed the pharmacological actions, synergistic effects, contraindications, and dosages of these herbs, and developed the initial formula of TJAOA103. Subsequently, we utilized multiple models to verify the safety and effectiveness of TJAOA103, and further optimized the formulation.

This is a prospective, single-arm clinical study designed to evaluate the safety and efficacy of the TCM formula TJAOA103 in women diagnosed with GSM. Using a pre-post analysis, we will assess the improvements in clinical symptoms, signs, sexual function, genitourinary health, and quality of life in participants with GSM following TJAOA103 administration to provide a safe and reliable novel therapeutic strategy for this population.

Being tested
TJAOA103
Keywords
Genitourinary Syndrome of Menopause, Traditional Chinise Medicine

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • TJAOA103Drug

    Once enrolled, participants will be administered TJAOA103 for 4 to 12 weeks. TJAOA103 should be taken orally twice a day, one sack each time. Dissolve it in about 200 mL of warm water and drink it all. Participants can take it half an hour before breakfast in the morning and half an hour before bedtime in the evening.

Study groups in NCT07160127
Study groupRoleWhat they receive
TJAOA103ExperimentalOnce enrolled, participants will be administered TJAOA103 for 4 to 12 weeks.
Receives: Drug: TJAOA103

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. severity of the most bothersome symptom (MBS)

    The MBS is derived from a selected list of common GSM symptoms, including vulvovaginal dryness, vulvovaginal itching/irritation, vulvovaginal burning/pain, dyspareunia, and dysuria/urinary frequency/urgency. At baseline, participants will be instructed to rate the severity of each symptom as absent (0), mild (1), moderate (2), or severe (3). They will then be asked to select a single MBS among those symptoms they classify as moderate or severe (i.e., a score ≥ 2). The MBS will be tracked through to the end of treatment, and the changes in its severity will be used to assess symptomatic improvement.

    Measured: From enrollment to the end of treatment at 4 or 12 weeks

Secondary outcomes (8)
  1. total score of GSM symptoms

    The total score, which ranges from 2 to 15, is the sum of the five individual symptom scores. The higher the score, the more severe the GSM symptoms are.

    Measured: From enrollment to the end of treatment at 4 or 12 weeks

  2. score for a specific GSM symptom

    The self-assessed severity score for a specific GSM symptom is assigned as 0, 1, 2, or 3 points, corresponding respectively to absent, mild, moderate, and severe.

    Measured: From enrollment to the end of treatment at 4 or 12 weeks

  3. Vaginal Health Index Score (VHIS)

    The total score of VHIS ranges from 5 to 25. The lower the score, the worse the vaginal health condition.

    Measured: From enrollment to the end of treatment at 4 or 12 weeks

  4. vaginal pH

    A pH level of 4.6 or above indicates vaginal atrophy.

    Measured: From enrollment to the end of treatment at 4 or 12 weeks

  5. Female Sexual Function Index-6 (FSFI-6)

    The score of FSFI-6 ranges from 2 to 30. A score of 19 or less is considered an indication of female sexual dysfunction.

    Measured: From enrollment to the end of treatment at 4 or 12 weeks

  6. Overactive Bladder Syndrome Score (OABSS)

    The total OABSS score ranges from 0 to 15. When the score for urinary urgency is 2 or higher, and the total OABSS score is 3 or higher, a diagnosis of overactive bladder syndrome (OAB) can be made. Generally, a total score of 3 to 5 indicates mild OAB, 6 to 11 indicates moderate OAB, and ≥12 indicates severe OAB.

    Measured: From enrollment to the end of treatment at 4 or 12 weeks

  7. score of International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF)

    The score of ICIQ-SF ranges from 0 to 21. A higher score indicates more severe urinary incontinence symptoms and a greater impact on the patient's daily life.

    Measured: From enrollment to the end of treatment at 4 or 12 weeks

  8. score of Menopause-Specific Quality of Life Questionnaire (MENQOL)

    The MENQOL consists of 4 domains, namely vasomotor, psychosocial, physical, and sexual functioning, with a total of 29 items. Participants are instructed to evaluate the existence and degree of bother from their symptoms using a 7-point Likert scale, where higher scores indicate a greater degree of bothersome symptoms. The score for each domain is calculated as the average score of its individual items. The total score is the mean of the four domain scores.

    Measured: From enrollment to the end of treatment at 4 or 12 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Sep 2025
  2. Study start15 Sep 2025 (estimated)
  3. Primary completion15 Jun 2027 (estimated)
  4. Study completion15 Sep 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
113 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07160127
Sponsor's protocol ID
TJ-IRB202508073-GSM
Status last verified
Sep 2025
First submitted
29 Aug 2025
Last updated
17 Sep 2025
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Early Phase 1 study testing TJAOA103 in people with Genitourinary Syndrome of Menopause (GSM), run by Tongji Hospital at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 17 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Jinjin Zhang, Associate Professor (+8613469995233, jinjinzhang@tjh.tjmu.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

severity of the most bothersome symptom (MBS) (time frame: From enrollment to the end of treatment at 4 or 12 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Sep 2025.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in